This is an open label study to compare three new generation TAU radioligands, 18F-RO948 (formerly known as 18F-6958948), 18F-MK6240, and [18F]GTP1for imaging of taupathy and demonstrate their absence of off-target binding in patients with Alzheimer disease (AD) and older healthy controls (OC). The study will directly compare AD and OC with these three next-generation TAU radioligands and compare each of them with historical data of the current most widely used first generation radioligand, 18F-AV1451. Upto38 (30 AD (Amyloid +)and 8 OC (Amyloid -), matched for age and sex with A+ subjects) male and female subjects aged 50-100 will be enrolled in this study protocol: up to 8 for Cohort 1, up to 8 for Cohort 2, and up to 22 for Cohort 3. The study consists of three cohorts: Cohort 1: Up to8 AD subjects (A+; CDR 0.5 and 1)will receive two PET scans in random order, with receiving either18F-RO948 or18F-MK6240 at the first scan. A third scan with 18F-GTP1is possible, depending on timing and radiotracer availability Cohort 2:Up to8 OC (A-; CDR=0)subjects will receive two PET scans in random order, with receiving either18F-RO948or 18F-MK6240 at the first scan. A third scan with 18F-GTP1is possible, depending on timing and radiotracer availability Cohort 3:Up to 22 (A+; CDR = 0, .5 and 1) subjects will receive three PET scans in random order, with receiving 18F-RO94818F-MK6240 or18F-GTP1at the first scan. Efforts will be made to include about 1/3 CDR = 0, 1/3 CDR .5, and 1/3 CDR 1 in Cohort 3.

开始日期2023-02-01

申办/合作机构

Washington University School of Medicine

[+1]

NCT04437290

/ Not yet recruitingN/AIIT

University of Washington Alzheimer's Disease Research Center (UW ADRC) Imaging & Biomarker Core

This is a cross-sectional, observational study that characterizes research participants with Alzheimer's disease (AD) for their patterns of brain degeneration with the investigational tau positron emission tomography (PET) radiotracer [18F] MK-6240. The goal is to describe the topographic pattern of involvement of cerebral brain regions (topographic phenotyping) in early stage AD participants using tau PET in a sub-cohort of the University of Washington Alzheimer's Disease Research Center (ADRC) Clinical Cohort, and to make this phenotype information available to affiliated research studies at the University of Washington and to the general scientific community via the National Alzheimer's Coordinating Center.

开始日期2022-11-01

申办/合作机构

University of Washington

[+2]

100 项与 Florquinitau F18 相关的临床结果

登录后查看更多信息

100 项与 Florquinitau F18 相关的转化医学

登录后查看更多信息

100 项与 Florquinitau F18 相关的专利（医药）

登录后查看更多信息

项与 Florquinitau F18 相关的文献（医药）

2024-06-01·Acta neuropathologica

Head-to-head comparison of [18F]-Flortaucipir, [18F]-MK-6240 and [18F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases

Article

作者: Neelamegam, Ramesh ; Frosch, Matthew P ; Normandin, Marc D ; Gómez-Isla, Teresa ; El Fakhri, Georges ; Dhaynaut, Maeva ; Moon, S-H ; Johnson, Keith ; Kumar, Sunny ; Aguero, Cinthya ; Amaral, Ana C ; Scapellato, Margaret ; Carazo-Casas, Carlos

Abstract:

We and others have shown that [18F]-Flortaucipir, the most validated tau PET tracer thus far, binds with strong affinity to tau aggregates in Alzheimer's (AD) but has relatively low affinity for tau aggregates in non-AD tauopathies and exhibits off-target binding to neuromelanin- and melanin-containing cells, and to hemorrhages. Several second-generation tau tracers have been subsequently developed. [18F]-MK-6240 and [18F]-PI-2620 are the two that have garnered most attention. Our recent data indicated that the binding pattern of [18F]-MK-6240 closely parallels that of [18F]-Flortaucipir. The present study aimed at the direct comparison of the autoradiographic binding properties and off-target profile of [18F]-Flortaucipir, [18F]-MK-6240 and [18F]-PI-2620 in human tissue specimens, and their potential binding to monoamine oxidases (MAO). Phosphor-screen and high resolution autoradiographic patterns of the three tracers were studied in the same postmortem tissue material from AD and non-AD tauopathies, cerebral amyloid angiopathy, synucleopathies, transactive response DNA-binding protein 43 (TDP-43)-frontotemporal lobe degeneration and controls. Our results show that the three tracers show nearly identical autoradiographic binding profiles. They all strongly bind to neurofibrillary tangles in AD but do not seem to bind to a significant extent to tau aggregates in non-AD tauopathies pointing to their limited utility for the in vivo detection of non-AD tau lesions. None of them binds to lesions containing β-amyloid, α-synuclein or TDP-43 but they all show strong off-target binding to neuromelanin and melanin-containing cells, as well as weaker binding to areas of hemorrhage. The autoradiographic binding signals of the three tracers are only weakly displaced by competing concentrations of selective MAO-B inhibitor deprenyl but not by MAO-A inhibitor clorgyline suggesting that MAO enzymes do not appear to be a significant binding target of any of them. These findings provide relevant insights for the correct interpretation of the in vivo behavior of these three tau PET tracers.

2024-05-01·European journal of nuclear medicine and molecular imaging

The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease

Article

作者: Quenon, Lisa ; Hanseeuw, Bernard ; Dricot, Laurence ; Gérard, Thomas ; Malotaux, Vincent ; Huyghe, Lara ; Salman, Yasmine ; Colmant, Lise ; Ivanoiu, Adrian ; Lhommel, Renaud

Abstract:

Purpose:

[18F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer’s disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our study aimed to evaluate whether cognitive impairment would be more closely associated with the spatial extent than with the intensity of tau-PET signal, as measured by the standard uptake value ratio (SUVr).

Methods:

[18F]MK6240 tau-PET data from 82 participants in the AD spectrum were quantified in three different brain regions (Braak ≤ 2, Braak ≤ 4, and Braak ≤ 6) using SUVr and the extent of tauopathy (EOT, percentage of voxels with SUVr ≥ 1.3). PET data were first compared between diagnostic categories, and ROC curves were computed to evaluate sensitivity and specificity. PET data were then correlated to cognitive performances and cerebrospinal fluid (CSF) tau values.

Results:

The EOT in the Braak ≤ 2 region provided the highest diagnostic accuracies, distinguishing between amyloid-negative and positive clinically unimpaired individuals (threshold = 9%, sensitivity = 79%, specificity = 82%) as well as between prodromal AD and preclinical AD (threshold = 38%, sensitivity = 81%, specificity = 93%). The EOT better correlated with cognition than SUVr (∆R2 + 0.08–0.09) with the best correlation observed for EOT in the Braak ≤ 4 region (R2 = 0.64). Cognitive performances were more closely associated with PET metrics than with CSF values.

Conclusions:

Quantifying [18F]MK-6240 tau PET in terms of EOT rather than SUVr significantly increases the correlation with cognitive performances. Quantification in the mesiotemporal lobe is the most useful to diagnose preclinical AD or prodromal AD.

2024-01-22·Journal of chemical information and modeling

Docking for Molecules That Bind in a Symmetric Stack with SymDOCK

Article

作者: Pepe, Joseph G. ; Shoichet, Brian K. ; Diamond, Marc I. ; Knight, Ian S. ; Shahmoradian, Sarah H. ; DeGrado, William F. ; Irwin, John J. ; Kormos, Rian C. ; Kunach, Peter ; Smith, Matthew S.

Discovering ligands for amyloid fibrils, such as those formed by the tau protein, is an area of great current interest. In recent structures, ligands bind in stacks in the tau fibrils to reflect the rotational and translational symmetry of the fibril itself; in these structures, the ligands make few interactions with the protein but interact extensively with each other. To exploit this symmetry and stacking, we developed SymDOCK, a method to dock molecules that follow the protein's symmetry. For each prospective ligand pose, we apply the symmetry operation of the fibril to generate a self-interacting and fibril-interacting stack, checking that doing so will not cause a clash between the original molecule and its image. Absent a clash, we retain that pose and add the ligand-ligand van der Waals energy to the ligand's docking score (here using DOCK3.8). We can check these geometries and energies using an implementation of ANI, a neural-network-based quantum-mechanical evaluation of the ligand stacking energies. In retrospective calculations, symmetry docking can reproduce the poses of three tau PET tracers whose structures have been determined. More convincingly, in a prospective study, SymDOCK predicted the structure of the PET tracer MK-6240 bound in a symmetrical stack to AD PHF tau before that structure was determined; the docked pose was used to determine how MK-6240 fit the cryo-EM density. In proof-of-concept studies, SymDOCK enriched known ligands over property-matched decoys in retrospective screens without sacrificing docking speed and can address large library screens that seek new symmetrical stackers. Future applications of this approach will be considered.

项与 Florquinitau F18 相关的新闻（医药）

2024-12-02

·Business Wire

Enigma Biomedical USA Announces Formation of Scientific Advisory Board

KNOXVILLE, Tenn.--( BUSINESS WIRE )--Enigma Biomedical USA ( EB USA ) today announced formation of its Scientific Advisory Board ( SAB ), comprised of top tier physicians and scientists from around the globe, spanning areas of expertise from chemistry, biology to medicine associated with the assessment and ultimate treatment of neurodegenerative diseases, such as Alzheimer’s Disease. Professor Serge Gauthier of McGill University, Montreal, Quebec, Canada will serve as Chairperson of the EB USA SAB, and will be joined by: Richard Hargreaves Ph.D., Senior Vice President Head of Neuroscience TRC, Bristol Myers Squibb, NJ, Kenji Ishii M.D. , Leader, Team for Neuroimaging Research Tokyo Metropolitan Institute of Gerontology, Japan, Keith Johnson M.D., Ph.D., Director, Molecular Neuroimaging, Department of Radiology Massachusetts General Hospital; Neurologist, Memory Disorders Unit, Department of Neurology, Brigham and Women's Hospital; and Professor of Radiology and Neurology, Harvard Medical School, MA, Sterling Johnson Ph.D., Jean R. Finley Professor of Geriatrics and Dementia, Department of Medicine Division of Geriatrics and Gerontology and Principal Investigator, Wisconsin Registry for Alzheimer’s Prevention (WRAP), The University of Wisconsin, WI, Eric M Reiman MD , Executive Director, Banner Alzheimer’s Institute and Chief Executive Officer, Banner Research; Professor of Psychiatry, University of Arizona; University Professor of Neuroscience, Arizona State University; Senior Scientist, Translational Genomics Research Institute; and Director, Arizona Alzheimer’s Consortium, Christopher Rowe FRACP M.D., Director of Molecular Imaging Research and a consultant neurologist to the Memory Disorders Clinic at the Austin Hospital, Australia, Koen Van Laere M.D., Ph.D., D.Sc., Head, Nuclear Medicine and Molecular Imaging, PET-MR Unit, Full Professor, Department of Imaging and Pathology, University Hospital Leuven-KU Leuven, Belgium, and Henrik Zetterberg M.D., Ph.D., Professor/ Chief Physician, Institute for neuroscience and Physiology, University of Gothenburg, Sweden; Group Leader, UK Dementia research Institute, University College London, UK; and Visiting Professor, The University of Wisconsin, WI “We are thrilled to assemble such a remarkably accomplished advisory board, and I am honored to serve as its chairperson. We have a unique mix of complementary expertise from basic sciences to clinical practice that will accelerate knowledge transfer and help persons living with neurodegenerative conditions and their care partners,” said Serge Gauthier, CM, C.Q., M.D., FRCPC, past Director of the McGill University Research Center for Studies in Aging and currently Professor Emeritus in Neurology and Psychiatry and co-lead of the Dementia Education Program at McGill University. “EBG USA greatly appreciates the commitment of these world-class researchers to work with us to advance our mission. We expect this collaboration to yield major strides toward addressing the unmet needs in neurodegenerative disease as well as providing future tools and technologies to support the development of disease modifying therapies,” said Rick Hiatt, President and CEO of EB USA. About Enigma Biomedical – USA Enigma Biomedical USA’s vision is to be the premier provider of imaging biomarkers for neurological pathologies, associated information technology, and related tools to accelerate the development, approval, and adoption of effective therapies to treat neurodegenerative diseases. EB’s neuroimaging biomarkers provide Pharma and Academic researchers with state-of-the-art tools for enabling Disease-Modifying Therapy development with the highest precision and accuracy. In pursuit of this vision, subsidiaries of EB have provided the best-in-class Tau and Amyloid PET imaging biomarkers, MK-6240 and NAV-4694, to our partners to enable their research efforts. Both tracers have recently been acquired by a third party for further development. EB also recently announced a partnership with AbbVie to explore their novel 4R Tau PET Imaging Biomarkers.

并购高管变更

2024-11-27

·先通医药

患者招募|先通医药一项III期临床研究招募阿尔茨海默病潜在患者

点蓝色字关注“先通医药” 尊敬的患者朋友：您好！中国人民解放军总医院第一医学中心正在开展一项“评价XTR006注射液正电子发射断层扫描（PET）视觉阅片用于检测老年受试者脑内神经原纤维缠结（NFTs）的有效性和安全性多中心III期临床研究”。该研究已获得国家药品监督管理局药物临床试验许可，以及医院伦理委员会批准，计划在全国约20家中心招募354例患者自愿参加。试验药物介绍医学界公认tau蛋白在大脑异常沉积是造成阿尔茨海默病（AD）的主要原因之一。目前普通的影像学方法无法判断患者脑内是否存在tau蛋白异常沉积及沉积的严重程度。XTR006注射液是国内外同步研发的、用于检测脑内tau蛋白异常沉积正电子放射断层显像（PET）显像剂，可在 PET上显示tau蛋白异常沉积的部位及严重程度，从而有助于您的病情得到正确诊断或评估病情的严重程度。主要入选标准如果您的年龄≥50周岁；且符合以下条件之一，可联系您的主治医生做进一步的评估：如果您的主治医生评估您不存在认知障碍，且β淀粉样蛋白（Aβ）-PET显像为阴性；或如果您的主治医生评估您存在认知障碍且Aβ-PET显像为阳性。联系方式如果有兴趣并想进一步了解该研究的详细情况，请在工作日8：00—11：30，14：30—17：00咨询以下人员： END 关于先通医药先通医药是中国创新放射性药物领域的领先企业，专注于放射性药物的研发创新及落地应用以改善患者的健康水平。先通医药于2014年正式开展新一代放射性药物的研发，总部位于北京，在上海设有研发中心，在江苏、广东、四川建设有现代化放射性药物智能生产基地；同时，在美国设有分支机构，并与十几家跨国药企达成战略合作。全球放射性药物主要应用于神经、心血管、肿瘤三大疾病领域，先通医药已实现全面布局，并拥有20+精准诊断和靶向治疗放射性药物研发管线。凭借自身的研发优势，先通医药获得了投资机构的青睐，2020年4月至今，已成功募资超20亿元人民币，未来不久将登陆主要资本市场，成为中国放射性药物领域的创新力量。

放射疗法临床3期

2024-11-20

·Business Wire

Veravas Completes Analytical Verification Study of the VeraBIND Tau Assay, a Groundbreaking Test to Measure Alzheimer's Tau Pathology in Blood

AUSTIN, Texas--( BUSINESS WIRE )--Veravas, a leading innovator in clinical diagnostics, today announced the results of an analytical verification study of its VeraBIND™ Tau assay, a next-generation test being co-developed with Phanes Biotech, an early-stage biotech company focused on treatments for neurodegenerative diseases, for the detection of Alzheimer’s disease (AD). The test is designed to detect and measure disease pathology to enable the diagnosis of AD at its earliest, most treatable stages. Unlike first-generation tests that measure biomarkers indicative of potential disease, VeraBIND Tau is designed to detect active disease by studying measurable binding activity occurring in the brain between hyperphosphorylated tau (HPT) and normal tau (nTau), which is a hallmark of AD. 1 The test can also aid in the diagnosis of AD, giving clinicians an accessible, accurate, and affordable alternative to tau PET imaging. AD is the sixth leading cause of death in the United States, afflicting an estimated 6.9 million Americans aged 65 or older. 2,3 It’s critical that clinicians have accessible tools to quickly and accurately diagnose and distinguish AD from other dementias causing cognitive impairment to enable targeted treatment. In AD, lifestyle modifications and emerging tau-directed therapies have shown promise in slowing or delaying cognitive decline. Veravas demonstrated VeraBIND Tau’s ability to accurately measure the pathological activity of hyperphosphorylated tau. In this analytical verification study, the test protocol was performed on 100 retrospectively collected patient samples, including 52 confirmed positive for AD tau pathology via F18 MK6240 tau PET imaging (of which, 19 had normal cognitive function, 21 had mild cognitive impairment, and 12 had dementia), 38 healthy controls, and 10 patients positive for beta amyloid plaques but negative by tau PET. 4 The data showed 94.2% sensitivity and 89.6% specificity resulting in an overall VeraBIND Tau assay agreement of 92.0% against tau PET imaging. “These analytical data show that VeraBIND Tau can measure active tau pathology of AD both among individuals with and without cognitive impairment,” said Bernard Hanseeuw, M.D., Ph.D., Associate Head of the Memory Clinic, Neurology Department, Saint Luc University Hospital in Belgium and Instructor at Mass General Hospital, Boston, MA. “The implementation of such a test could not only one day speed the diagnosis of AD, it could also be used to inform the development and testing of tau-directed therapeutics. It also holds great promise for non-AD tauopathies, as the assay proved positive in 7 out of 8 cases tested with low-amyloid, and positive tau-PET data”. To co-develop the VeraBIND Tau assay, the companies used Veravas’s proprietary VeraBIND technology, a platform that is designed to capture and purify key proteins in blood to enable highly accurate protein detection and characterization. When combined with antibodies, VeraBIND magnetic nanobeads act as a filter for multiple sample types, enabling the removal of interfering substances that can obscure the biomarker of interest and potentially produce false results. This patented technology makes it possible to study low-abundance disease-causing proteins that may otherwise be undetectable by enriching samples pre-analytically to improve the detectability of the analyte. “These results demonstrate the transformative potential of VeraBIND Tau to upend the standard of care for management of patients suspected of potentially having Alzheimer’s disease,” said Josh Soldo, Chief Scientific Officer at Veravas. "Our highly accurate analytical test protocol can be performed quickly and cost-effectively and could potentially eliminate both the uncertainties associated with biomarker detection tests and the high costs and wait times associated with tau PET imaging, thereby helping clinicians get answers to their patients much more rapidly.” “The VeraBIND Tau assay will enable Alzheimer’s disease diagnosis for the first time in geographies where tau PET imaging is not available” said Khalid Iqbal, Chief Scientific Officer of Phanes Biotech. For more information about the VeraBIND Tau assay and other VeraBIND products, visit www.veravas.com . About Veravas Veravas is a leading innovator in clinical diagnostics focused on early-stage detection and prognostic screening for Alzheimer’s disease and other neurological conditions. The company’s proprietary VeraBIND™ technology transforms challenging sample types into measurable biomarkers, enabling earlier disease detection and the development of novel diagnostic tests. Its VeraBIND Tau assay is a first-in-class blood-based test that measures the pathological activity of hyperphosphorylated tau in blood samples of cognitively normal individuals or individuals experiencing cognitive impairment which may be used to aid in the diagnosis of Alzheimer's disease. Learn more at Veravas.com or follow us on LinkedIn . About Phanes Biotech Phanes Biotech is an early-stage biotech company focused on developing breakthrough treatments for neurodegenerative diseases, including Alzheimer’s, macular degeneration, traumatic brain injury, stroke, Down syndrome-associated Alzheimer’s, and cognitive aging. Phanes takes a unique and differentiated approach to Alzheimer’s and other neurodegenerative diseases, setting it apart from existing therapies and drugs currently in development. The company’s pipeline includes innovative drugs: (1) Neuroregenerative small molecule P021 – This promising therapeutic aims to address Alzheimer’s disease by shifting the balance from neurodegeneration toward neural regeneration. (2) Immunotherapy PB43D – A potent, high-affinity antibody designed to target and bind to tau. It is the only antibody shown to reduce both tau and Aβ pathologies. Through a strategic partnership, Phanes leverages its portfolio of tau-targeting antibodies to develop a groundbreaking, first-in-class blood-based assay. This innovative diagnostic tool aims to detect and measure tau pathology activity in the brain, setting a new standard for diagnosing and tracking the progression of Alzheimer’s disease. Learn more at Phanesbiotech.com or follow us on LinkedIn . Thal DR, Tomé SO. The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death. Brain Res Bull. 2022;190:204-217. doi:10.1016/j.brainresbull.2022.10.006 Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimer’s Dement 2024;20(5)." Ahmad FB, Cisewski JA, Anderson RN. Mortality in the United States — Provisional Data, 2023. MMWR Morb Mortal Wkly Rep 2024;73:677–681. DOI: http://dx.doi.org/10.15585/mmwr.mm7331a1 . Gérard T, et al. The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2024 May;51(6):1662-1674.

临床结果免疫疗法

100 项与 Florquinitau F18 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
轻度认知障碍	临床3期	中国	北京先通国际医药科技股份有限公司	2024-11-01
阿尔茨海默症	临床3期	美国	University of California	2018-05-01
认知功能障碍	临床3期	美国	University of California	2018-05-01
神经变性	临床3期	美国	University of California	2018-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SNMMI2022	N/A	-	-	[18F]MK6240 (Healthy Controls (CTRL))	鹽獵鏇鹽繭壓醖獵鑰選(窪窪選顧繭鹽艱選繭齋) = 憲觸觸鹹艱範襯壓積築夢衊積遞蓋醖鹹餘鹹窪 (鏇製繭餘襯壓壓鏇鏇壓, 0.03) 更多	-	2022-08-08
				[18F]MK6240 (Mild Cognitive Impairment (MCI))	鹽獵鏇鹽繭壓醖獵鑰選(窪窪選顧繭鹽艱選繭齋) = 繭顧齋選顧窪衊觸選鏇夢衊積遞蓋醖鹹餘鹹窪 (鏇製繭餘襯壓壓鏇鏇壓, 0.05)
AAIC2022	N/A	阿尔茨海默症 \| 衰老	-	18F-MK6240 (Aβ+ve CU)	積壓願製觸積餘鬱積廠(築顧願憲蓋鏇廠膚淵餘) = 廠範淵鬱糧窪壓衊網構憲壓鑰觸齋遞鹹獵鑰淵 (鏇製夢製襯構選遞獵繭 ) 更多	-	2022-02-01
				18F-MK6240 (Aβ+ve CI)	淵願窪鏇齋遞膚觸製製(積夢窪醖構繭願製積淵) = 繭齋壓餘蓋膚製鑰鹹鬱醖襯選繭積鹽繭廠膚範 (製獵獵遞廠獵廠範選選 )
AAIC2020	N/A	-	-	F-18 MK6240 (Ab +ve CN)	醖構襯夢衊獵襯壓鹹窪(構鬱糧鏇願鑰憲鹹鏇範) = 積鹹願壓簾醖獵鑰衊觸艱簾廠憲壓積簾鏇淵觸 (鬱範壓窪製齋廠齋鏇遞 )	-	2020-12-07
				F-18 MK6240 (MCI)	醖構襯夢衊獵襯壓鹹窪(構鬱糧鏇願鑰憲鹹鏇範) = 繭鏇網衊顧鏇餘膚願觸艱簾廠憲壓積簾鏇淵觸 (鬱範壓窪製齋廠齋鏇遞 )
SNMMI2020	N/A	-	-	MK-6240 ([18F]-MK6240)	醖膚鏇齋製鏇構網鑰艱(構窪遞鹽網齋製鹽觸鏇) = 艱淵窪範觸淵鹽選觸構製製鏇衊鏇鏇衊繭獵構 (醖網願積鑰鬱鏇簾鑰顧 ) 更多	-	2020-05-15
AAIC2019	N/A	-	-	18F-MK-6240 (Amyloid-positive controls with tau pathology)	蓋鑰齋夢願糧憲壓製憲(顧夢遞顧簾鏇網範獵餘) = 遞選鹹製簾網獵願蓋鏇繭觸糧淵鹹觸衊製鏇繭 (鑰鏇廠鹽壓壓獵夢醖衊 )	-	2019-07-01
				18F-MK-6240 (Amyloid-positive patients with low tau pathology)	蓋鑰齋夢願糧憲壓製憲(顧夢遞顧簾鏇網範獵餘) = 壓齋遞夢選衊製糧遞積繭觸糧淵鹹觸衊製鏇繭 (鑰鏇廠鹽壓壓獵夢醖衊 )
NCT02562989 (6240-001 \| MK-6240-001, CTgov)	临床1期	阿尔茨海默症 \| 轻度认知障碍	13	[18F]MK-6240, ~185 MBq (Part 1, Healthy Young Participants)	鹹襯衊蓋衊壓網願願艱(壓遞窪艱艱築顧廠膚構) = 衊網衊構鏇遞夢壓願夢繭鏇網夢餘簾範鹹顧網 (襯積鬱鑰壓簾選齋鬱艱, 壓願鏇繭鹹鹹餘構窪淵 ~ 遞遞鏇憲蓋糧獵窪顧願) 更多	-	2018-07-23
				[18F]MK-6240, ~160 MBq (Part 2, Healthy Elderly Participants)	鹹襯衊蓋衊壓網願願艱(壓遞窪艱艱築顧廠膚構) = 鹹壓願鹽範顧淵憲製遞繭鏇網夢餘簾範鹹顧網 (襯積鬱鑰壓簾選齋鬱艱, 襯艱繭淵簾鏇鑰憲衊簾 ~ 選選觸簾遞壓蓋繭範膚) 更多
AAIC2016	N/A	-	-	[18F]MK-6240	夢窪築襯窪積糧鑰窪繭(積製襯願選鹹簾鏇築鹹) = 夢繭獵膚積簾獵繭醖鹽鹹衊鹹構膚鑰壓壓餘淵 (繭顧選憲齋願範顧餘艱 ) 更多	-	2016-07-01
AAIC2016	N/A	-	-	[18F]MK-6240	齋簾鑰膚鹽積膚鹽網顧(鹹鹽簾遞簾鬱鹽膚艱顧) = 淵廠醖鏇蓋鬱憲餘糧蓋鹽觸簾醖鹽壓艱獵窪壓 (襯齋衊鏇築夢鬱衊製繭 ) 更多	-	2016-07-01